Neurogene (NASDAQ:NGNE) Price Target Raised to $72.00

Neurogene (NASDAQ:NGNE) had its price target increased by Robert W. Baird from $54.00 to $72.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an outperform rating on the stock.

Separately, HC Wainwright dropped their target price on shares of Neurogene from $51.00 to $49.00 and set a “buy” rating for the company in a report on Monday, August 12th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $63.33.

Neurogene Trading Down 5.9 %

Neurogene stock traded down $2.31 during mid-day trading on Tuesday, hitting $36.89. 144,574 shares of the company traded hands, compared to its average volume of 139,768. The stock has a fifty day moving average price of $47.11 and a 200-day moving average price of $40.11. Neurogene has a one year low of $12.49 and a one year high of $74.49.

Hedge Funds Weigh In On Neurogene

A number of hedge funds have recently modified their holdings of the company. FMR LLC grew its holdings in Neurogene by 912.4% during the 3rd quarter. FMR LLC now owns 731,801 shares of the company’s stock valued at $30,706,000 after buying an additional 659,515 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Neurogene by 906.5% during the 1st quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock valued at $25,831,000 after purchasing an additional 457,062 shares during the last quarter. Jennison Associates LLC purchased a new position in shares of Neurogene during the third quarter valued at about $3,300,000. Integral Health Asset Management LLC purchased a new stake in shares of Neurogene in the second quarter worth about $2,547,000. Finally, Driehaus Capital Management LLC boosted its stake in Neurogene by 123.8% during the second quarter. Driehaus Capital Management LLC now owns 102,187 shares of the company’s stock valued at $3,719,000 after buying an additional 56,533 shares during the last quarter. 52.37% of the stock is currently owned by institutional investors.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.